ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

We aren’t showing our typical comparisons because the provider updated his/her primary specialty after we conducted our analysis. The updated address appears on this page.

Psychiatry

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,514Medicare Part D Prescriptions Filled, Including Refills
$625K Total Retail Price of All Prescriptions
714 Patients Receiving at Least One Drug in Part D
11%Patients 65 Years and Older
2% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
ZOLPIDEM TARTRATE 657 33
PAROXETINE HCL 613 70
SERTRALINE HCL 522 53
FLUOXETINE HCL 498 30
CYMBALTA 483 17
BUPROPION XL 387 42
CITALOPRAM HBR 361 39
VENLAFAXINE HCL ER 359 43
TRAZODONE HCL 333 34
DOXEPIN HCL 280 14
RISPERIDONE 276 53
SEROQUEL XR 229 11
BUSPIRONE HCL 228 22
GABAPENTIN 222 14
VENLAFAXINE HCL 180 20
HYDROXYZINE PAMOATE 149 15 R
AMITRIPTYLINE HCL 146 0 R
DONEPEZIL HCL 132 69
ZOLPIDEM TARTRATE ER 131 13 10
CLONAZEPAM 127 0
QUETIAPINE FUMARATE 126 0
BUPROPION HCL SR 114 0
SEROQUEL 113 0
BUDEPRION XL 90 0 10
ABILIFY 90 0
DIVALPROEX SODIUM 87 0
BENZTROPINE MESYLATE 82 18 R
TRIFLUOPERAZINE HCL 76 0
DIVALPROEX SODIUM ER 71 0
PRISTIQ ER 59 0
LITHIUM CARBONATE 57 13
OLANZAPINE 54 0
MIRTAZAPINE 53 0
NAMENDA 52 27
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Sept. 12, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.